October 27, 2007 -- Last week, two China biopharmas made announcements about gene therapy drugs. Sunway Biotech of Shanghai reached an agreement with Genzyme to co-develop an experimental gene therapy drug that aids the growth of blood vessels. Meanwhile, Aida Pharma provided an update on a second gene therapy drug, this one for cancer. TPG paid more than $30 million for a 20%-25% stake in ChemPartner, a CRO based in Shanghai. AstraZeneca will begin sourcing a key ingredient of its blockbuster anti-psychotic, Seroquel, in China. And AMDL began marketing a new injectable anti-aging skin care product in China. More details...
